Breaking News

ViroCell Biologics Completes Oversubscribed Convertible Note Offering

Proceeds will accelerate its growth as it continues to gain commercial traction with its specialist services in viral vector design and manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor

ViroCell Biologics, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) specializing in GMP viral vector manufacturing for clinical trials, has completed an oversubscribed convertible note offering led by new investor First Light Asset Management LLC plus existing investors including Sartorius Stedim Biotech S.A. and Dorset Opportunity Fund LP.   Proceeds will accelerate ViroCell’s growth as it continues to gain commercial traction with its specialist servi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters